AK132 is an asymmetric bispecific antibody with a "1+1" valency, designed to simultaneously target and block CLDN18.2 and CD47. It features a wild-type IgG1 Fc structure and is currently in the ...

Long An International Port is working with a number of global shipping companies to implement plans to transport goods ...